Kungekudala, i-JYMed Technology Co., Ltd. yazisa ukuba i-Leuprorelin Acetate, eveliswe yi-subsidiary yayo i-Hubei JX Bio-Pharmaceutical Co., Ltd., iphumelele ngempumelelo ukuhlolwa kokubhaliswa kweziyobisi.
Isishwankathelo seMarike yeZiyobisi yokuqala
I-Leuprorelin Acetate liyeza elitofwayo elisetyenziselwa ukunyanga izifo ezixhomekeke kwihomoni, kunye ne-molecular formula C59H84N16O12•xC2H4O2. I-gonadotropin-releasing hormone agonist (GnRHa) esebenza ngokuthintela inkqubo ye-pituitary-gonadal. Ekuqaleni yaphuhliswa ngu-AbbVie kunye ne-Takeda Pharmaceutical, eli chiza lithengiswa phantsi kwamagama eemveliso ezahlukeneyo kumazwe ahlukeneyo. EUnited States, ithengiswa phantsi kwegama elithi LUPRON DEPOT, ngelixa e-China, ithengiswa njengeYina Tong.
Inkqubo ecacileyo kunye neendima ezichazwe kakuhle
Ukususela ngo-2019 ukuya ku-2022, uphando lwamachiza kunye nophuhliso lwagqitywa, lulandelwa kukubhaliswa kwe-API ngo-Matshi 2024, xa isaziso sokwamkelwa sifunyenwe. Ukuhlolwa kokubhaliswa kweziyobisi kwapasiswa ngo-Agasti 2024. I-JYMed Technology Co., Ltd. yayinoxanduva lophuhliso lwenkqubo, uphuhliso lwendlela yohlalutyo, izifundo zokungacoceki, ukuqinisekiswa kwesakhiwo, kunye nokuqinisekiswa kwendlela. I-Hubei JX Bio-Pharmaceutical Co., Ltd. yayiphethe inkqubo yokuqinisekisa ukuveliswa, ukuqinisekiswa kwendlela yokuhlalutya, kunye nezifundo zokuzinza kwi-API.
Ukwandiswa kweMarike kunye neMbango eKhulayo
Ukunyuka kwezehlo zomhlaza wesibeleko kunye ne-uterine fibroids kuqhuba imfuno eyongeziweyo ye-Leuprorelin Acetate. Imakethi yaseMntla Melika ngoku ilawula imakethi ye-Leuprorelin Acetate, kunye nenkcitho yezempilo ekhulayo kunye nokwamkelwa okuphezulu kobuchwepheshe obutsha ibe yeyona nto iphambili yokukhula. Ngaxeshanye, imakethi yaseAsia, ngakumbi iChina, ikwabonisa imfuno emandla yeLeuprorelin Acetate. Ngenxa yokusebenza kwalo, imfuno yehlabathi yeli chiza iyenyuka, kwaye ubungakanani bemarike kulindeleke ukuba bufikelele kwi-USD 3,946.1 yezigidi ngo-2031, okubonisa isantya sokukhula sonyaka (CAGR) se-4.86% ukusuka ngo-2021 ukuya ku-2031.
Malunga JYMed
I-Shenzhen JYMed Technology Co., Ltd. (emva koku ebizwa ngokuba yi-JYMed) yasekwa ngo-2009, igxile kuphando, uphuhliso, imveliso, kunye nokuthengiswa kweepeptides kunye neemveliso ezinxulumene ne-peptide. Ngeziko elinye lophando kunye neziseko ezintathu eziphambili zemveliso, i-JYMed yenye yabavelisi abakhulu bee-APIs ze-peptide ezenziwe ngamachiza e-China. Iqela eliphambili lenkampani le-R&D liqhayisa ngaphezulu kweminyaka engama-20 yamava kwishishini le-peptide kwaye liphumelele ngempumelelo uhlolo lwe-FDA kabini. Inkqubo yoshishino ye-peptide ebanzi kunye nesebenzayo ye-JYMed inikezela abathengi uluhlu olupheleleyo lweenkonzo, kubandakanywa uphuhliso kunye nokuveliswa kweepeptide zonyango, iipeptide zezilwanyana, i-antimicrobial peptides, kunye ne-cosmetic peptides, kunye nokubhaliswa kunye nenkxaso yokulawula.
Imisebenzi yoShishino oluPhambili
1.Ubhaliso lwasekhaya kunye nolwamazwe ngamazwe lwe-peptide APIs
2.Izilwanyana zezilwanyana kunye ne-cosmetic peptides
3.Custom peptides kunye CRO, CMO, OEM iinkonzo
Amachiza e-4.PDC (i-peptide-radionuclide, i-peptide-imolekyuli encinci, i-peptide-protein, i-peptide-RNA)
Ukongeza kwi-Leuprorelin Acetate, i-JYMed ingenise iifayili zokubhalisa kunye ne-FDA kunye ne-CDE kwezinye iimveliso ze-API ezininzi, kubandakanywa namachiza eklasi ye-GLP-1RA aziwayo ngoku njenge-Semaglutide, i-Liraglutide kunye ne-Tirzepatide. Abathengi bexesha elizayo abasebenzisa iimveliso ze-JYMed baya kukwazi ukubhekisela ngokuthe ngqo kwinombolo yobhaliso ye-CDE okanye inombolo yefayile ye-DMF xa befaka izicelo zokubhalisa kwi-FDA okanye kwi-CDE. Oku kuya kunciphisa kakhulu ixesha elifunekayo ukulungiselela amaxwebhu ezicelo, kunye nexesha lokuvavanya kunye neendleko zokuphononongwa kwemveliso.
Qhagamshelana nathi
IShenzhen JYMed Technology Co., Ltd.
Idilesi:Imigangatho yesi-8 neye-9, iSakhiwo soku-1, i-Shenzhen Biomedical Innovation Industrial Park, iNombolo ye-14 yeJinhui Road, iSithili saseKengzi, iSithili sasePingshan, eShenzhen
Ifowuni:+86 755-26612112
Iwebhusayithi:http://www.jymedtech.com/
Ixesha lokuposa: Aug-29-2024